Cargando…
Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction
Truncated tissue factor (tTF), retargeted to tumor vasculature by GNGRAHA peptide (tTF-NGR), and doxorubicin have therapeutic activity against a variety of tumors. We report on combination experiments of both drugs using different schedules. We have tested fluorescence- and HPLC-based intratumoral p...
Autores principales: | Stucke-Ring, Janine, Ronnacker, Julian, Brand, Caroline, Höltke, Carsten, Schliemann, Christoph, Kessler, Torsten, Schmidt, Lars Henning, Harrach, Saliha, Mantke, Verena, Hintelmann, Heike, Hartmann, Wolfgang, Wardelmann, Eva, Lenz, Georg, Wünsch, Bernhard, Müller-Tidow, Carsten, Mesters, Rolf M., Schwöppe, Christian, Berdel, Wolfgang E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347705/ https://www.ncbi.nlm.nih.gov/pubmed/27738341 http://dx.doi.org/10.18632/oncotarget.12559 |
Ejemplares similares
-
NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor
por: Brand, Caroline, et al.
Publicado: (2016) -
Animal Safety, Toxicology, and Pharmacokinetic Studies According to the ICH S9 Guideline for a Novel Fusion Protein tTF-NGR Targeting Procoagulatory Activity into Tumor Vasculature: Are Results Predictive for Humans?
por: Berdel, Wolfgang E., et al.
Publicado: (2020) -
Potential therapeutic impact of CD13 expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017) -
Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer
por: Schmidt, Lars Henning, et al.
Publicado: (2017) -
Targeting Tissue Factor to Tumor Vasculature to Induce Tumor Infarction
por: Berdel, Andrew F., et al.
Publicado: (2021)